Lyell Immunopharma Investor Relations Material
Latest events
M&A Announcement
Lyell Immunopharma
Q2 2025
12 Aug, 2025
Q1 2025
13 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Lyell Immunopharma Inc
Access all reports
Lyell Immunopharma Inc is a biotechnology company focused on developing cell-based immunotherapies for cancer treatment. The company specializes in genetically engineering T cells to enhance their persistence, potency, and functionality against solid tumors. Lyell Immunopharma conducts research and development activities in collaboration with academic and industry partners. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Key slides for Lyell Immunopharma Inc
43rd Annual J.P. Morgan Healthcare Conference 2025
Lyell Immunopharma Inc
M&A Announcement
Lyell Immunopharma Inc
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
LYEL
Country
🇺🇸 United States